
Sign up to save your podcasts
Or


The reopening story from an investment perspective is different in many parts of the world. Portfolio manager Jed Weiss provides insights on a rather uneven international recovery and where he is seeing opportunities. Jed manages the Fidelity International Growth Fund. He says that Covid has been disruptive for several industries, but disruption can lead to investment opportunities. He adds that he's finding opportunities in travel software, commercial catering, and aerospace, noting that aerospace companies have been given the opportunity to cut costs in the market. Jed also notes that he sees investment opportunities in both China and more developed economies. He believes that once the recent regulatory initiatives have been solved, the big tech platforms in China are likely to be the dominant players in the future. Jed also discusses various opportunities in the health care sector. He says blood-plasma based drugs are part of an oligopoly with significant barriers to entry.
Recorded on August 13, 2021.
Transcript (PDF): https://www.fidelity.ca/cs/Satellite/doc/transcript_podcast_weiss_13aug.pdf
By Fidelity Canada4.9
88 ratings
The reopening story from an investment perspective is different in many parts of the world. Portfolio manager Jed Weiss provides insights on a rather uneven international recovery and where he is seeing opportunities. Jed manages the Fidelity International Growth Fund. He says that Covid has been disruptive for several industries, but disruption can lead to investment opportunities. He adds that he's finding opportunities in travel software, commercial catering, and aerospace, noting that aerospace companies have been given the opportunity to cut costs in the market. Jed also notes that he sees investment opportunities in both China and more developed economies. He believes that once the recent regulatory initiatives have been solved, the big tech platforms in China are likely to be the dominant players in the future. Jed also discusses various opportunities in the health care sector. He says blood-plasma based drugs are part of an oligopoly with significant barriers to entry.
Recorded on August 13, 2021.
Transcript (PDF): https://www.fidelity.ca/cs/Satellite/doc/transcript_podcast_weiss_13aug.pdf

530 Listeners

2,182 Listeners

941 Listeners

288 Listeners

52 Listeners

2,029 Listeners

2,135 Listeners

212 Listeners

920 Listeners

72 Listeners

84 Listeners

1,569 Listeners

337 Listeners

353 Listeners

6 Listeners